Abstract
Maternal HIV-1–specific antibodies are efficiently transferred to newborns, but their role in disease control is unknown. We administered neutralizing IgG, including the human neutralizing monoclonal IgG1b12, at levels insufficient to block infection, to six newborn macaques before oral challenge with simian-HIV strain SF162P3 (SHIVSF162P3). All of the macaques rapidly developed neutralizing antibodies and had significantly reduced plasma viremia for six months. These studies support the use of neutralizing antibodies in enhancing B cell responses and viral control in perinatal settings.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Change history
29 December 2010
In the version of this article initially published, the original received date was 27 April 2007. The correct received date is 27 April 2010. The error has been corrected in the HTML version of the article.
References
Richman, D.D., Wrin, T., Little, S.J. & Petropoulos, C.J. Proc. Natl. Acad. Sci. USA 100, 4144–4149 (2003).
Steimer, K.S., Scandella, C.J., Skiles, P.V. & Haigwood, N.L. Science 254, 105–108 (1991).
Li, Y. et al. Nat. Med. 13, 1032–1034 (2007).
Burton, D.R. et al. Science 266, 1024–1027 (1994).
Wu, X. et al. J. Virol. 80, 835–844 (2006).
Shibata, R. et al. Nat. Med. 5, 204–210 (1999).
Mascola, J.R. et al. Nat. Med. 6, 207–210 (2000).
Baba, T.W. et al. Nat. Med. 6, 200–206 (2000).
Hessell, A.J. et al. PLoS Pathog. 5, e1000433 (2009).
Hessell, A.J. et al. Nat. Med. 15, 951–954 (2009).
Forthal, D.N., Landucci, G., Phan, T.B. & Becerra, J. J. Virol. 79, 2042–2049 (2005).
Forthal, D.N. et al. J. Virol. 80, 9217–9225 (2006).
Haigwood, N.L. et al. J. Virol. 78, 5983–5995 (2004).
Yamamoto, H., Kawada, M., Takeda, A., Igarashi, H. & Matano, T. PLoS ONE 2, e540 (2007).
Jayaraman, P. et al. J. Virol. 81, 822–834 (2007).
Hessell, A.J. et al. Nature 449, 101–104 (2007).
Moir, S. et al. J. Exp. Med. 205, 1797–1805 (2008).
Walker, L.M. et al. Science 326, 285–289 (2009).
Wu, X. et al. Science 329, 856–861 (2010).
Acknowledgements
We would like to thank Z. Brower for technical support, D. Morris and K. Filer for manuscript preparation, M.L. Marthas and K.K.A. Van Rompay for advice on subcutaneous dosing of IgG and oral inoculation of infants, J. Overbaugh (Fred Hutchinson Cancer Research Center) for the Env-deleted viral backbone plasmid Q23ΔEnv, S. Barnett and I. Srinivasan (Novartis) for recombinant gp120-SF162 and V. Planelles (University of Utah) for the plasmid pEMC*. M. Piatak and J.D. Lifson (Science Applications International Corporation) kindly provided RNA standards and advice on real-time PCR. SHIVSF162P3 was supplied by N. Miller (US National Institutes of Health Division of AIDS) and R. Pal (Advanced Bioscience Labs). TZM-bl were supplied by the US National Institutes of Health AIDS Research Reference Reagent Program. This study was supported by grants from the US National Institutes of Health R01HD038653 (N.L.H.), R01AI33292 (D.R.B.) and R01AI052039 (D.N.F.) and from the Elizabeth Glaser Pediatric AIDS Foundation (N.L.H.).
Author information
Authors and Affiliations
Contributions
C.T.N., J.P.J., W.F.S. and G.L. were responsible for experimental work, analyses and preparation of figures; P.D. and L.K. provided macaque care and clinical and laboratory assessments; D.A. oversaw the study at the Washington National Primate Research Center; C.T.N., D.N.F., D.R.B., D.A. and P.J. contributed to the writing of the manuscript; B.A.R. performed the statistical analyses; D.R.B. provided IgG1b12; N.L.H. was responsible for study design and coordination and writing the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Text and Figures
Supplementary Figures 1–7, Supplementary Table 1 and Supplementary Methods (PDF 360 kb)
Rights and permissions
About this article
Cite this article
Ng, C., Jaworski, J., Jayaraman, P. et al. Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques. Nat Med 16, 1117–1119 (2010). https://doi.org/10.1038/nm.2233
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.2233
This article is cited by
-
Broadly neutralizing anti-HIV-1 antibodies tether viral particles at the surface of infected cells
Nature Communications (2022)
-
Single-dose bNAb cocktail or abbreviated ART post-exposure regimens achieve tight SHIV control without adaptive immunity
Nature Communications (2020)
-
Antibody-mediated prevention and treatment of HIV-1 infection
Retrovirology (2018)
-
Development of broadly neutralizing antibodies in HIV-1 infected elite neutralizers
Retrovirology (2018)
-
Broadly neutralizing antibodies: What is needed to move from a rare event in HIV-1 infection to vaccine efficacy?
Retrovirology (2018)